Alumis Inc.

Stage 4 · Declining · week 5

As of Oct 22, 2026, Alumis is in Stage 4, the downtrend phase, now in week 5 (since Sep 18, 2026). It closed at $6.82, 77.5% below its 52-week high and below its 200-day average, which is falling.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. More about the company

$6.82

+0.15% today

$883M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ALMS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-06-28 → 2026-10-22

S? 42w

S4 18w

S1 13w

S2 21w

S3 12w

2024-06-282026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S4 18w → S1 13w → S2 21w → S3 12w → S2 8w → S3 2w → S4 5w current

Total tracked: 121 weeks across 8 stage runs.

ALMS among Biotechnology99th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…99	ALMSAlumis Inc.	Stage 4 · wk 5	85	−8.3%

vs 52W High

-77.5%

$4.49 lo$30.30 hi

77.5% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 5

1w13w26w

Week 5, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-68.8%

200 DMA: $21.83 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.50x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-8.3%

-75.6%

-73.8%

YTD

-23.8%

+47.0%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 5 · Vol 0.50x

2026-10-21S4

Wk 5 · Vol 0.33x

2026-10-20S4

Wk 5 · Vol 0.51x

2026-10-19S4

Wk 5 · Vol 0.50x

2026-10-16S4

Wk 5 · Vol 0.85x

2026-10-15S4

Wk 4 · Vol 0.96x

2026-10-14S4

Wk 4 · Vol 0.80x

2026-10-13S4

Wk 4 · Vol 0.67x

2026-10-12S4

Wk 4 · Vol 0.56x

2026-10-09S4

Wk 4 · Vol 0.48x

2026-10-08S4

Wk 3 · Vol 1.02x

2026-10-07S4

Wk 3 · Vol 0.78x

Moving averages & range

50 DMA

$11.98

200 DMA

$21.83

52W High

$30.30

52W Low

$4.49

5D Low

$6.12

Resistance levels (recent highs)

20d High

$7.39

60d High

$28.95

120d High

$30.30

250d High

$30.30

Next resistance

+8.4%

to 20d High

ROE

-93.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.9

Alumis: quick answers

What stage is Alumis in?

As of Oct 22, 2026, Alumis (ALMS) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 18, 2026 and is in week 5. What the four stages mean

Is Alumis in an uptrend?

No. Alumis is in a Stage 4 downtrend. It trades 68.8% below its 200-day average, which is falling.

How far is Alumis from its 52-week high?

Alumis closed at $6.82 on Oct 22, 2026, 77.5% below its 52-week high of $30.30. Its 52-week low is $4.49.

How has Alumis performed over the past year?

As of Oct 22, 2026, Alumis is up 47.0% over the past year and down 23.8% so far in 2026.

Which sector and industry is Alumis in?

Alumis is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.